Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

References for PMC Articles for PubMed (Select 23155356)

1.

Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.

Hansen TF, Jakobsen A.

Pharmacogenomics. 2011 Dec;12(12):1681-93. doi: 10.2217/pgs.11.118. Review.

PMID:
22118052
2.

Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology.

Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B.

Endokrynol Pol. 2011;62(5):456-64. Review.

3.

Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology.

Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudła B.

Endokrynol Pol. 2011;62(5):444-55. Review.

4.

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L.

Mol Aspects Med. 2011 Apr;32(2):88-111. doi: 10.1016/j.mam.2011.04.004. Epub 2011 May 6. Review.

PMID:
21565214
5.

Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis.

Cao C, Fang JJ, Ying T, Sun SF, Lv D, Chen ZB, Ma HY, Yu YM, Ding QL, Shu LH, Deng ZC.

Arch Med Res. 2010 Oct;41(7):548-57. doi: 10.1016/j.arcmed.2010.09.006.

PMID:
21167395
6.

TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T.

J Exp Clin Cancer Res. 2010 Jul 20;29:100. doi: 10.1186/1756-9966-29-100.

7.

Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.

Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T.

Int J Med Sci. 2010 Jan 31;7(1):48-54.

8.

Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T.

Int J Med Sci. 2009 Sep 28;6(6):305-11.

9.

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.

Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.

Mol Cancer Ther. 2009 Sep;8(9):2496-508. doi: 10.1158/1535-7163.MCT-09-0302. Epub 2009 Sep 15. Review.

10.

The role of vascular endothelial growth factor genetic variability in cancer.

Schneider BP, Radovich M, Miller KD.

Clin Cancer Res. 2009 Sep 1;15(17):5297-302. doi: 10.1158/1078-0432.CCR-08-2576. Epub 2009 Aug 25.

11.

Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study.

Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, Mertens AC.

J Clin Oncol. 2009 May 10;27(14):2328-38. doi: 10.1200/JCO.2008.21.1425. Epub 2009 Mar 30. Review.

12.

Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.

Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, Ito H, Yamashita T.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):122-8. doi: 10.1016/j.ijrobp.2008.10.075. Epub 2009 Mar 26.

PMID:
19327900
13.

Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.

Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K.

Adv Drug Deliv Rev. 2009 May 20;61(5):388-401. doi: 10.1016/j.addr.2008.10.005. Epub 2008 Dec 24. Review.

PMID:
19135108
14.

VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.

Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T.

Ther Drug Monit. 2008 Aug;30(4):497-503. doi: 10.1097/FTD.0b013e318180e3d2.

PMID:
18641541
15.

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.

Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ; ASCO Cancer Survivorship Expert Panel.

J Clin Oncol. 2007 Sep 1;25(25):3991-4008. Epub 2007 Jun 18. Review.

PMID:
17577017
16.

Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.

Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T.

Am J Clin Oncol. 2007 Jun;30(3):252-7.

PMID:
17551301
17.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C.

J Clin Oncol. 2007 Apr 1;25(10):1160-8.

18.

Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M.

J Gastroenterol. 2006 May;41(5):425-32.

PMID:
16799883
19.

Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.

Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S.

Jpn J Clin Oncol. 2005 Jun;35(6):316-23. Epub 2005 Jun 16.

20.

Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma.

Miki I, Tamura T, Nakamura T, Makimoto H, Hamana N, Uchiyama H, Shirasaka D, Morita Y, Yamada H, Aoyama N, Sakaeda T, Okumura K, Kasuga M.

Ther Drug Monit. 2005 Jun;27(3):369-74.

PMID:
15905809
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk